Premium
Effects of the dopamine‐related drug bromocriptine on event‐related potentials and its relation to the law of initial value
Author(s) -
NISHIMURA NAOYUKI,
OGURA CHIKARA,
OHTA IKUYA
Publication year - 1995
Publication title -
psychiatry and clinical neurosciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.609
H-Index - 74
eISSN - 1440-1819
pISSN - 1323-1316
DOI - 10.1111/j.1440-1819.1995.tb01863.x
Subject(s) - bromocriptine , latency (audio) , n100 , event related potential , dopamine , psychology , placebo , medicine , anesthesia , audiology , cognition , neuroscience , prolactin , hormone , computer science , telecommunications , alternative medicine , pathology
Effects of the dopamine‐related drug bromocriptine (BCT) on event‐related potentials (ERP) were investigated in 18 healthy volunteers. Bromocriptine 2.5 mg or an inactive placebo was administered according to a completely randomized double‐blind, cross‐over design. The ERP were recorded 3 h after medication was given. Although BCT prolonged the P300 latency, it had no effect on the amplitudes of the ERP components as a whole. Bromocriptine increased the latencies of N100, P200 and P300 in the respective short‐latency subject group, and decreased the latency of N200 in the long‐latency subject group. It increased the amplitude of N200 in the low‐amplitude subject group. It was concluded that the prolongation of P300 latency as a whole and the different responses that take place are dependent on the initial values and were recognized in the effect of a single administration of BCT 2.5 mg. The results of this study are discussed in relation to the law of initial value.